Table 1.
Baseline demographics and disease characteristics
| Sofosbuvir–velpatasvir 12 weeks N = 51 | Sofosbuvir–velpatasvir plus ribavirin 12 weeks N = 51 | |
|---|---|---|
| Mean age (range) (years) | 66 (43, 82) | 66 (41, 83) |
| Female sex | 33 (65) | 29 (57) |
| Mean body mass index (range) (kg/m2) | 26.5 (20.4, 43.0) | 25.8 (18.3, 58.6) |
| HCV genotype and subtype | ||
| Genotype 1 | 41 (80) | 39 (76) |
| Genotype 1a | 1 (2) | 0 |
| Genotype 1b | 40 (78) | 39 (76) |
| Genotype 2 | 9 (18) | 11 (22) |
| Genotype 2 (no confirmed subtype) | 5 (10) | 5 (10) |
| Genotype 2a | 0 | 2 (4)a |
| Genotype 2a/2c | 2 (4) | 1 (2) |
| Genotype 2b | 2 (4) | 4 (8) |
| Genotype 3b | 1 (2) | 0 |
| Mean HCV RNA (range) (log10 IU/mL) | 5.7 (3.7–7.1) | 5.8 (4.2–7.0) |
| IL28B CC genotype | 33 (65) | 37 (73) |
| CPT B [7–9]b | 40 (78) | 39 (76) |
| MELD score ≤ 15 | 46 (90) | 48 (94) |
| Ascites | ||
| None | 19 (37) | 16 (31) |
| Mild/moderate | 32 (63) | 33 (65) |
| Severe | 0 | 2 (4) |
| Encephalopathy | ||
| None | 23 (45) | 22 (43) |
| Medication-controlled | 28 (55) | 29 (57) |
| No prior HCV treatment | 27 (53) | 31 (61) |
| Mean estimated glomerular filtration rate (range) (mL/min)c | 93 (40, 183) | 89 (42, 299) |
Data presented are n (%) unless stated otherwise
CPT Child–Pugh–Turcotte
aOne patient with missing HCV genotype was subsequently determined to have genotype 2a HCV infection by BLAST analysis
bThe CPT score was calculated using prothrombin activation percentage for the coagulation parameter
cThe estimated glomerular filtration rate was calculated using the Cockcroft–Gault equation